A groundbreaking study conducted by researchers at Washington State University (WSU) has unveiled compelling evidence suggesting that even a singular…
Read More
UCB Acquires Candid Therapeutics for Up to $2.2 Billion to Bolster Autoimmune Disease Pipeline with Novel T-Cell Engagers
UCB’s strategic move to acquire Candid Therapeutics for an initial $2 billion upfront, with an additional $200 million in milestone…
Read More
Johns Hopkins Researchers Identify Key Protein and Gas Signaling Pathway as Potential Target for Alzheimer’s Disease Treatment
Researchers at Johns Hopkins Medicine have unveiled a significant breakthrough in the understanding of Alzheimer’s disease, identifying a specific protein…
Read More
Brain Immune System Response Linked to Early Loss of Smell in Alzheimer’s Disease Patients
The decline of the olfactory sense has long been observed as a precursor to the cognitive deterioration associated with Alzheimer’s…
Read More
Chiesi Acquires KalVista Pharmaceuticals for $1.9 Billion, Bolstering Rare Disease Portfolio with On-Demand HAE Treatment
In a landmark move that marks the largest acquisition in its 90-year history, Italian pharmaceutical giant Chiesi has agreed to…
Read More
With CDC testing paused, clinical labs are stepping up to sustain surveillance and protect timely disease detection.
The Centers for Disease Control and Prevention (CDC), a cornerstone of the nation’s public health infrastructure, has initiated a temporary…
Read More
Evolutionary Selection and Paternal Age How Aging Increases Disease-Causing Mutations in Sperm
The long-held scientific assumption that the male germline is a static repository of genetic information has been fundamentally challenged by…
Read More
FDA Approves Auvelity for Alzheimer’s Disease Agitation, Offering a Novel Treatment Option
The U.S. Food and Drug Administration (FDA) has granted approval to Axsome Therapeutics’ Auvelity (dextromethorphan HBr and bupropion HCl) for…
Read More
Study: Toxic Exposure in Pregnancy May Drive Disease Risk Across Generations
A groundbreaking study from Washington State University (WSU) has unveiled startling evidence suggesting that a singular exposure to a common…
Read More
BioMarin Pharmaceutical Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Bolstering Rare Disease Portfolio
BioMarin Pharmaceutical has officially concluded its substantial acquisition of Amicus Therapeutics, a move that promises to significantly expand BioMarin’s footprint…
Read MoreYOU MAY HAVE MISSED
